

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 0690)

CHANGES IN BOARD AND COMMITTEES MEMBERS

The Board announces that with effect from 15 November 2017,

- (1) Mr. Ren Qimin has been appointed as an independent non-executive Director and a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee;
- (2) Ms. Lau Chau In has been appointed as a non-executive Director;
- (3) Dr. Carl Aslan Jason Morton Firth has resigned as an independent non-executive Director;
- (4) Dr. Carl Aslan Jason Morton Firth has ceased to be the chairman of the Remuneration Committee and a member of each of the Audit Committee and the Nomination Committee; and
- (5) Mr. Chow Kai Ming has been appointed as the chairman of the Remuneration Committee.

* For identification purpose only

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF EACH OF THE AUDIT COMMITTEE, THE REMUNERATION COMMITTEE AND THE NOMINATION COMMITTEE OF THE BOARD

The board (“**Board**”) of directors (“**Directors**” and each a “**Director**”) of Uni-Bio Science Group Limited (“**Company**”, together with its subsidiaries, the “**Group**”) wishes to announce that with effect from 15 November 2017, Mr. Ren Qimin (“**Mr. Ren**”) has been appointed as (i) an independent non-executive Director; (ii) a member of the audit committee (“**Audit Committee**”) of the Board; (iii) a member of the remuneration committee (“**Remuneration Committee**”) of the Board and (iv) a member of the nomination committee (“**Nomination Committee**”) of the Board.

The biographical details of Mr. Ren are set out below:

Mr. Ren, aged 62, has more than 24 years of management experience. He was the Deputy Secretary General and Executive Director of the board of directors of the China Association for International Friendly Contact for 10 years, primarily responsible for affairs relating to the Chinese Government and arranging meetings for international governmental agencies, political parties, other commercial organization and senior Chinese governmental authorities. He served as a director and a senior management in several companies since 1993 to present. Previously, Mr. Ren was the senior advisor of the Beijing office of CIGNA Corporation, a global health insurance service company from 1997 to 1999 primarily responsible for government relation affairs. Prior to that, Mr. Ren was also the General Manager of 蓋洛普（中國）諮詢有限公司 (unofficial english translation being Gallup (China) Consulting Limited) which mainly provides market research and polling service, and is a joint-venture set up by a Chinese investor and Gallup Inc. a global performance-management consulting company. Mr. Ren was primarily responsible for assisting it to start its operations in China from 1993 to 1996. Currently, he serves as an executive director of Carta Group Limited, a company principally engaged in international public relations and governmental affairs consultancy service. He obtained a Master Degree in Economics from Anhui University in 1990.

As at the date of this announcement, Mr. Ren did not have any interest in the shares or underlying shares in the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, Mr. Ren does not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement, or any other position with the Company and other members of the Group or possess any other major professional qualifications.

Mr. Ren has entered into a letter of appointment with the Company for a term of 3 years, subject to retirement by rotation in accordance with the articles of association of the Company. Mr. Ren is entitled to a director’s fee of HK\$240,000 per annum which is determined by the Board with reference to his background, qualification, experience, duties and responsibilities.

Mr. Ren confirmed that he met the independence criteria as set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”). Mr. Ren has no relationship with any Directors, senior management or substantial shareholders of the Company.

Save as disclosed above, the Company is not aware of any information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter in relation to the appointment of Mr. Ren as an independent non-executive Director that needs to be brought to the attention of the shareholders of the Company.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board also wishes to announce that with effect from 15 November 2017, Ms. Lau Chau In (“**Ms. Lau**”) has been appointed as a non-executive Director.

The biographical details of Ms. Lau are set out below:

Ms. Lau, aged 25, has approximately 3 years of management experience. She has served as a director in several private companies in the PRC. Ms. Lau is currently serving as a director of a number of companies within HeungKong Group, a PRC based conglomerate with business segments ranging from trade logistics, industrial development, healthcare, financial investments, education, development and construction. She obtained a Bachelor Degree of Business Administration from The George Washington University in 2015.

As at the date of this announcement, Ms. Lau did not have any interest in the shares or underlying shares in the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, Ms. Lau does not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement, or any other position with the Company and other members of the Group or possess any other major professional qualifications.

Ms. Lau has entered into a letter of appointment with the Company for a term of 3 years, subject to retirement by rotation in accordance with the articles of association of the Company. Ms. Lau is entitled to a director’s fee of HK\$240,000 per annum which is determined by the Board with reference to her background, qualification, experience, duties and responsibilities.

Save as disclosed above, the Company is not aware of any information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter in relation to the appointment of Ms. Lau as a non-executive Director that needs to be brought to the attention of the shareholders of the Company.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Dr. Carl Aslan Jason Morton Firth (“**Dr. Firth**”) has resigned as an independent non-executive Director, a member of the Audit Committee, the Chairman of the Remuneration Committee and a member of the Nomination Committee of the Board with effect from 15 November 2017, in view of his other business commitments that requires his full time attention. Dr. Firth has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation or other matter that shall be brought to the attention of The Stock Exchange of Hong Kong Limited and the Company’s other directors, shareholders, creditors and the insured under the Company’s insurance.

The Company would like to take this opportunity to express its warmest gratitude to Dr. Firth for his contribution during the tenure of his service at the Company and would like to welcome Mr. Ren and Ms. Lau to join the Board.

CHANGE OF CHAIRMAN OF THE REMUNERATION COMMITTEE

Upon Dr. Firth’s resignation, he has ceased to be the chairman of the Remuneration Committee and Mr. Chow Kai Ming has been appointed as the chairman of the Remuneration Committee with effect from 15 November 2017.

By order of the Board of
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 15 November 2017

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Kingsley Leung (Chairman) and Mr. Chen Dawei (Vice-chairman); one non-executive Director, Ms. Lau Chau In and three independent non-executive Directors, namely, Mr. Zhao Zhi Gang and Mr. Chow Kai Ming and Mr. Ren Qimin.